Objective
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europe's leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification using functional genomics technologies including whole genome sequencing and genetic complementation of resistant mutants, yeast three hybrid, click chemistry and proteomics. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. Innovative techniques, based on microfluidics and array platforms, will be used for hit ranking, determining rates of cidality and confirming mechanism of action. Medicinal chemistry will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.
Fields of science
Call for proposal
FP7-HEALTH-2010-single-stage
See other projects for this call
Funding Scheme
CP-IP - Large-scale integrating projectCoordinator
1015 Lausanne
Switzerland
Participants (26)
Participation ended
560024 Bangalore
751 05 Uppsala
27100 Pavia
CB2 1TN Cambridge
Participation ended
E1 4NS London
75724 Paris Cedex 15
119071 Moscow
35122 Padova
814 99 Bratislava
1022 Budapest
NR4 7UH Norwich
560012 Bangalore
560066 Bangalore
13100 Vercelli
94010 Burlingame Ca
48940 Leioa
41126 Modena
50009 Zaragoza
8092 Zuerich
07749 Jena
91380 Chilly Mazarin
7701 Rondebosch
Participation ended
1025 Saint Sulpice
75654 Paris
1015 Lausanne
65929 Frankfurt Am Main